 |
Collaboration
Oncothyreon has granted a license to Merck KGaA of Darmstadt, Germany for the development of Stimuvax®. Merck KGaA is responsible worldwide for clinical development, manufacturing, including process development and scale-up for commercial manufacturing, and marketing. Oncothyreon is eligible for cash payments based on the achievement of certain process transfer events, for BLA submission for first and second cancer indications, for regulatory approval for first and second cancer indications, and for sales milestones. Oncothyreon will receive a royalty based on net sales.
|
|
